 phase II study mitoxantrone thiotepa autologous marrow support patients relapsed breast cancer effect high-dose chemotherapy treatment advanced metastatic breast cancer second active high-dose noncross-resistant regimen tandem customary high-dose regimen cyclophosphamide cisplatin CVP phase II trial high-dose mitoxantrone hours days MVT patients metastatic breast cancer advanced chemotherapy-refractory breast cancer patients ineligible high-dose CVP chemotherapy amount prior treatment poor-response status patients cycle grade toxicity second cycle MVT Overall patients complete response CR partial responders first cycle CR second cycle overall response rate overall median freedom progression months overall median survival months Toxicity mucositis grade results high-dose MVT significant activity patients Administration second cycle high-dose therapy MVT CR rate morbidity mortality second cycle first cycle high incidence grade mucositis regimen follow-up study high-dose mitoxantrone